Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical giant Pfizer has discontinued a development program in lung cancer for PF-3512676, an investigational compound, in combination with cytotoxic chemotherapy.
Subscribe to our email newsletter
This includes two phase 3 clinical trials and two phase 2 clinical trials. Pfizer licensed PF- 3512676 from Coley Pharmaceutical in 2005.
An analysis of the trials by independent data safety monitoring committee (DSMC) found that there was no that there was no evidence that the compound produced additional clinical efficacy over that achieved with the standard cytotoxic chemotherapy regimen alone.
The DSMC concluded that the risk-benefit profile did not justify continuation of the trials. Pfizer agreed with the committee’s findings.
The drug, which Bear Stearns predicted would generate sales of $384 million in 2010 if it came to market, is a minor setback for Pfizer, whose shares fell by 50 cents, or 1.9%. Coley, however, was on the receiving end of a 58.25% share fall. According to CNN, the discontinued compound was the company’s most advanced pipeline candidate, and sales would have brought it significant royalty revenue.